Unicycive Faces Securities Class Action Over Manufacturing Disclosure Lapses
New York – September 11, 2026 -- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers, alleging violations of federal securities laws tied to the company's handling of a third-party manufacturing vendor's compliance issues.
Lawsuit covers investors who purchased Unicycive stock between December 29, 2025 and June 29, 2026
The complaint alleges Unicycive failed to inspect or audit its third-party manufacturing vendor's facility for compliance with current good manufacturing practices (cGMP). As a result, the company allegedly lacked a reasonable basis to claim the vendor had remedied deficiencies previously cited by the U.S. Food and Drug Administration.